In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The impact of diabetes mellitus and microvascular complications on heart failure biomarkers

Session Poster Session 3

Speaker Florina Fringu

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Comorbidities
  • Session type : Poster Session

Authors : F Fringu (Cluj Napoca,RO), D Zdrenghea (Cluj Napoca,RO), G Gusetu (Cluj Napoca,RO), B Caloian (Cluj Napoca,RO), H Comsa (Cluj Napoca,RO), A Bian (Cluj Napoca,RO), D Gurzau (Cluj Napoca,RO), R Tomoaia (Cluj Napoca,RO), C Florea (Cluj Napoca,RO), F Morar (Cluj Napoca,RO), D Pop (Cluj Napoca,RO)

Authors:
F Fringu1 , D Zdrenghea2 , G Gusetu1 , B Caloian1 , H Comsa1 , A Bian2 , D Gurzau1 , R Tomoaia1 , C Florea1 , F Morar2 , D Pop1 , 1University of Medicine and Pharmacy of Cluj Napoca, Rehabilitation Cardiology Department Cluj-Napoca - Cluj Napoca - Romania , 2Clinical Rehabilitaion Hospital, Cardiology Department - Cluj Napoca - Romania ,

Citation:

Background: The prevalence of heart failure (HF) is increased in diabetic patients. Several studies confirmed the prognostic role of ST2 and Galectin-3 (Gal-3) in HF patients, but the relationship between diabetes mellitus (DM) along with its complications and the new biomarkers is still uncertain.
Methods:  88 subjects with decompensated heart failure (NYHA classes III-IV) were enrolled, with a mean age of 69.82 ± 9.5 years, 61.7% of which were men and 47.9% of them with previous DM. All patients were evaluated both clinically and echocardiographically. The entire cohort had serum concentrations of ST2, Gal-3 and NT-proBNP measured upon admission. Patients with DM were divided into two groups: those with DM microvascular complications (retinopathy, nephropathy or polyneuropathy - 58.9%) or without- 41.1%. 
Results:  Mean left ventricular ejection fraction (LVEF) was 38.84 ± 11.3%,  without significant differences between the two groups (p-NS).
Concerning HF biomarkers, the following mean values were obtained: ST2 - 46.32 ± 25.8 ng/ml, Gal 3-15.19 ± 6.7 ng/ml, NT-pro BNP - 3493.04 ± 3884.8 pg/ml. There were no statistically significant differences between patients with or without DM: ST2 : 47.51 ± 28.7ng/ml  vs 44.89 ± 23.1 ng/ml; Gal-3: 15.25 ± 7.7ng/ml vs 15.07 ± 5.7ng/ml; NT-proBNP: 3857.42 ± 3844.2 pg/ml vs 3104.28 ± 3940.4 pg/ml. 
When comparing the two groups of diabetic subjects, only Gal-3 values were found to be consistently higher in subjects with microvascular complications: 16.23 ± 4.9 ng/ml  vs 13.74 ± 10.4 ng/ml (p=0.005); ST2 : 53.21 ± 31.9ng/ml  vs 39.5 ± 23.3 ng/ml (p-NS); NT-proBNP : 4364.9 ± 4213.9 pg/ml vs 3188.96 ± 3350.0 pg/ml (p=NS).
ST 2 levels correlated significantly with NT-proBNP levels (r=0.24; p=0.03), hypocholesterolemia (r= 0.22; p=0.048) and GFR (r=-0.22) in both groups. There was no direct correlation between ST2 levels and the NYHA class (p=0.334). Gal-3 levels also correlated well with LVEF value (r=0.22; p=0.048), NT-pro BNP levels (r=0.40; p < 0.0001) and NYHA class (p <0.0001). 
Conclusions: Biomarkers of HF used for screening the general population are also useful in patients with DM, with Galectin-3 levels being significantly higher in diabetic patients with microvascular complications than in those without.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are